









Markets
/
Stocks
/
nasdaq-tem
/

Tempus AI Inc

TEM

88.900USD

+0.060+0.07%

Close 10/29, 16:00（ET）Quotes delayed by 15 min

15.44BMarket Cap

LossP/E TTM



Tempus AI Inc

88.900

+0.060+0.07%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Tempus AI Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Tempus AI Inc's Score

Industry at a Glance

Industry Ranking

96 / 407

Overall Ranking

200 / 4623

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

85.474

Target Price

-1.29%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Tempus AI Inc Highlights

StrengthsRisks

Tempus AI, Inc. is a technology company. The Company provides next generation diagnostics across multiple disease areas, with technology capabilities, harnessing the data and analytics to help personalize medicine. The Company’s product lines include genomics, data, and artificial intelligence applications (AI). Its genomics product line leverages its laboratories to provide next generation sequencing, diagnostics, polymerase chain reaction (PCR), profiling, molecular genotyping, and other anatomic and molecular pathology testing. The Company's AI applications are focused on developing and providing diagnostics that are algorithmic in nature, implementing new software as a medical device, and building and deploying clinical decision support tools. Its primary product of AI applications is Next, an AI platform that leverages machine learning to apply an intelligent layer onto routinely generated data to proactively identify and minimize care gaps for oncology and cardiology patients.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 116.24% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 693.40M.

Overvalued

The company’s latest PE is 41.45, at a high 3-year percentile range.

Institutional Buying

The latest institutional holdings are 74.63M shares, increasing 2.48% quarter-over-quarter.

Held by Catherine Wood

Star Investor Catherine Wood holds 7.42M shares of this stock.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 7.76, which is higher than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 314.63M, representing a year-over-year increase of 89.57%, while its net profit experienced a year-over-year increase of 92.41%.

Score

Industry at a Glance

Previous score

7.76

Change



Financials

6.12

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

5.84

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.33

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.52

Key Metrics

Free cash flow

No Data

Tempus AI Inc's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.30, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is 41.45, which is 16.22% below the recent high of 48.18 and 154.58% above the recent low of -22.62.

Score

Industry at a Glance

Previous score

7.30

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 96/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 7.73, which is lower than the Biotechnology & Medical Research industry's average of 8.01. The average price target for Tempus AI Inc is 88.00, with a high of 105.00 and a low of 65.00.

Score

Industry at a Glance

Previous score

7.73

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

85.474

Target Price

-1.29%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

520

Total

Median

Average

Company name

Ratings

Analysts

Tempus AI Inc

TEM

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 7.04, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 101.47 and the support level at 79.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.90

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.828

Neutral

RSI(14)

50.890

Neutral

STOCH(KDJ)(9,3,3)

44.321

Neutral

ATR(14)

6.010

Low Volatility

CCI(14)

-51.856

Neutral

Williams %R

64.700

Sell

TRIX(12,20)

0.170

Sell

StochRSI(14)

43.683

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

88.655

Buy

MA10

88.890

Buy

MA20

91.556

Sell

MA50

84.995

Buy

MA100

74.284

Buy

MA200

64.679

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.21. The latest institutional shareholding proportion is 44.24%, representing a quarter-over-quarter decrease of 45.66%. The largest institutional shareholder is Baillie Gifford, holding a total of 12.09M shares, representing 7.17% of shares outstanding, with 18.11% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Blue Media, LLC

18.14M

-29.78%

BK TL21 LLC

15.22M

Baillie Gifford & Co.

Star Investors

12.09M

-1.60%

Lefkofsky (Eric Paul)

11.72M

+158.25%

Red Sky LLC

9.50M

-17.83%

Gray Media, LLC

9.27M

-1.42%

The Vanguard Group, Inc.

Star Investors

7.72M

+28.73%

ARK Investment Management LLC

Star Investors

7.42M

-1.06%

SoftBank Group Corp

5.41M

Amova Asset Management Co., Ltd.

3.87M

-9.06%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 4.91, which is higher than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.00. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.